Kailera Therapeutics' stock experienced a significant decline of 5.35% during Monday's intraday trading session.

The sharp drop followed the company's announcement that it has adopted amended and restated bylaws in connection with its IPO closing. The new bylaws establish advance-notice procedures for stockholder proposals at meetings and formalize the process for director nominations.

These corporate governance changes align the bylaws with provisions in the restated charter, including implementing a classified board structure. Investors may have reacted negatively to these changes, which could be perceived as potentially limiting shareholder influence and making it more difficult for stockholders to propose changes or nominate directors.